HotSpot Therapeutics recently announced FDA clearance of our Investigational New Drug (IND) application for HST-1011, our small molecule allosteric inhibitor […]
Subscribe and get notified about new posts.
What Took So Long? – How Tech Has Finally Caught Up with Transcription Factors
HotSpot Therapeutics recently announced a strategic collaboration with AbbVie to develop IRF5 transcription factor inhibitors for autoimmune diseases. The following blog post provides some valuable real-world perspective on why this initiative is such an important breakthrough in immunology therapeutics.
A Turning Point for Immuno-Oncology
Immunotherapy has been the holy grail in the fight against cancer for the last decade. For good reason, we’ve been […]
Hacking the Human Cell – How Once ‘Un-druggable’ Proteins Became the New Frontier in Drug Development
White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system […]
A Global Community
It is in moments like this that we are reminded of the collective power of good to overcome the disenfranchised and of the incredible impact of even the smallest gestures to shape the course of history.
Staying Human in the Age of Artificial Intelligence
No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI technology will absolutely […]
Making R&D ‘Smarter’ by Putting Artificial Intelligence into Practice
The pharmaceutical industry still faces unrelenting challenges across the entirety of the drug development landscape. According to Piper Sandler’s recent […]
Hitting the Spot
Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing. This infusion of capital will enable HotSpot to transition into a clinical stage company while supporting further pipeline and platform growth.
Immuno-Oncology: The Comeback Kid
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families.
